Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization

Liver International

Volumn 30, Issue 1, 2010, Pages 77-84

  Hsu, Chia Yang ^a,b   Huang, Yi Hsiang ^a,b   Su, Chien Wei ^a,b   Lin, Han Chieh ^a,b   Chiang, Jen Huey ^a,b   Lee, Pui Ching ^a   Lee, Fa Yauh ^a,b   Huo, Teh Ia ^a,b   Lee, Shou Dong ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Ascites; Cirrhosis; Contrast medium; Hepatocellular carcinoma; Transarterial chemoembolization

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; SODIUM;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ASCITES; CANCER MORTALITY; CANCER SURVIVAL; CHEMOEMBOLIZATION; FEMALE; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SODIUM BLOOD LEVEL; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS; ASCITES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMORBIDITY; FEMALE; HEPATIC ARTERY; HUMANS; INCIDENCE; KIDNEY FAILURE, ACUTE; LIVER NEOPLASMS; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL RATE; TAIWAN;

EID: 73349095027     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02128.x     Document Type: Article

References (40)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-43.
2. Pocobelli G, Cook LS, Brant R, et al. Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver Int 2008; 28: 1272-9.
3. Bruix J, Llovet J.M. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-24.
4. Akamatsu M, Yoshida H, Obi S, et al. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver Int 2004; 24: 625-9.
5. Huang YH, Chen CH, Chang TT, et al. The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multicenter study. Liver Int 2004; 24: 419-24.
6. Cardenas A, Gines P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 2001; 34: 671-6.
7. Laragh JH, Cannon PJ, Bentzel CJ, et al. Angiotensin II, norepinephrine, and renal transport of electrolytes and water in normal man and in cirrhosis with ascites. J Clin Invest 1963; 42: 1179-92.
8. Eckardt K.U. Renal failure in liver disease. Intensive Care Med 1999; 25: 5-14.
9. Lodhia N, Kader M, Mayes T, et al. Risk of contrastinduced nephropathy in hospitalized patients with cirrhosis. World J Gastroenterol 2009; 15: 1459-64.
10. Huo TI, Wu JC, Huang YH, et al. Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome. Aliment Pharmacol Ther 2004; 19: 999-1007.
11. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
12. Grant BF, Dufour MC, Harford T.C. Epidemiology of alcoholic liver disease. Semin Liver Dis 1988; 8: 12-25.
13. Huo TI, Lin HC, Lee FY, et al. Occurrence of cirrhosisrelated complications is a time-dependent prognostic predictor independent of baseline model for end-stage liver disease score. Liver Int 2006; 26: 55-61.
14. Gonwa TA, Jennings L, Mai ML, et al. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 2004; 10: 301-9.
15. Poggio ED, Nef PC, Wang X, et al. Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis 2005; 46: 242-52.
16. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-12.
17. Papadakis MA, Arieff A.I. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med 1987; 82: 945-52.
18. Bataller R, Gines P, Arroyo V, et al. Hepatorenal syndrome. Clin Liver Dis 2000; 4: 487-507.
19. Huang YS, Chiang JH, Wu JC, et al. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. Am J Gastroenterol 2002; 97: 1223-7.
20. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391-479.
21. Barrett BJ, Parfrey P.S. Preventing nephropathy induced by contrast medium. N Engl J Med 2006; 354: 379-86.
22. Cho YK, Chung JW, Kim JK, et al. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer 2008; 112: 352-61.
23. Huo TI,Wu JC, Lee PC, et al. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int 2004; 24: 210-5.
24. Fernandez-Rodriguez CM, Prieto J, et al. Arteriovenous shunting, hemodynamic changes, and renal sodium retention in liver cirrhosis. Gastroenterology 1993; 104: 1139-45.
25. Kew MC, Brunt PW, Varma RR, et al. Renal and intrarenal blood-flow in cirrhosis of the liver. Lancet 1971; 2: 504-10.
26. Barnardo DE, Summerskill WH, Strong CG, et al. Renal function, renin activity and endogenous vasoactive substances in cirrhosis. Am J Dig Dis 1970; 15: 419-25.
27. Bichet DG, Van Putten VJ, Schrier R.W. Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N Engl J Med 1982; 307: 1552-7.
28. Bichet D, Szatalowicz V, Chaimovitz C, et al. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 1982; 96: 413-7.
29. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation 2006; 113: 1799-806.
30. Massicotte A. Contrast medium-induced nephropathy: strategies for prevention. Pharmacotherapy 2008; 28: 1140-50.
31. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25.
32. Evidence-based colloid use in the critically ill: American Thoracic Society Consensus Statement. Am J Respir Crit Care Med 2004; 170: 1247-59.
33. Wong PY, Carroll RE, Lipinski TL, et al. Studies on the renin-angiotensin-aldosterone system in patients with cirrhosis and ascites: effect of saline and albumin infusion. Gastroenterology 1979; 77: 1171-6.
34. Gines P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493-502.
35. Luca A, Garcia-Pagan JC, Bosch J, et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology 1995; 22: 753-8.
36. Huo TI, Wu JC, Lee PC, et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998; 28: 231-6.
37. Huo TI, Lin HC, Hsia CY, et al. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol 2007; 102: 1920-30.
38. Huo TI, Lin HC, Huang YH, et al. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer 2006; 107: 141-8.
39. Huo TI, Lin HC, Hsia CY, et al. The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey. Dig Liver Dis 2008; 40: 882-9.
40. Huo TI, Lui WY, Wu JC, et al. Deterioration of hepatic functional reserve in patients with hepatocellular carcinoma after resection: incidence, risk factors, and association with intrahepatic tumor recurrence. World J Surg 2004; 28: 258-62.